Laboratory Medicine Program

MYD88

Clinical Decription:
The L265P activating mutation in the MYD 88 gene is present in the majority of patients with lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), approximately 50% IgM monoclonal gammopathy of undetermined significance (MGUS), and 30-40% activated B-cell –like subtype of diffuse large B-cell lymphoma. This mutation is also useful in selecting targeted therapy with BTK inhibitors in the treatment of WM.

Method: PCR

Component Tests Used: n/a

Reference Ranges Used:
Reference ranges for this test are not available online. However, they are included in all test results. For more information, please call us.

Specimen Type: Peripheral Blood/Bone Marrow/FFPE
Volume: n/a

Shipping: room temperature or 4C

Special Instructions: Test will be billed to referring hospital, laboratory, physician or medical group. See requisitions for the full list of available testing and special instructions.

Testing Schedule(s): Please call

Turnaround Time: None

For more information, call 416.340.5227 or 1.866.865.5227